Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1973 1
1981 1
1984 2
1985 1
1986 6
1987 2
1988 12
1989 22
1990 37
1991 30
1992 25
1993 23
1994 23
1995 12
1996 4
1997 6
1998 3
1999 1
2000 2
2001 1
2002 2
2003 1
2004 2
2005 2
2006 2
2007 2
2008 1
2009 1
2012 1
2019 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 8387882

229 results

Results by year

Filters applied: . Clear all
Page 1
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al. Sznol M, et al. J Natl Cancer Inst. 1992 Jun 17;84(12):929-37. doi: 10.1093/jnci/84.12.929. J Natl Cancer Inst. 1992. PMID: 1629914
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
Gambacorti-Passerini C, Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM. Gambacorti-Passerini C, et al. J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):43-8. doi: 10.1097/00002371-199301000-00006. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8435431 Clinical Trial.
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grima KM, Fisher RI, Boldt DH, Doroshow JH, et al. Gaynor ER, et al. J Natl Cancer Inst. 1990 Sep 5;82(17):1397-402. doi: 10.1093/jnci/82.17.1397. J Natl Cancer Inst. 1990. PMID: 2388289
229 results